Seeking Alpha

RTI Biologics (RTIX -13.5%) trades down into the close despite beating Q4 estimates. Profit...

RTI Biologics (RTIX -13.5%) trades down into the close despite beating Q4 estimates. Profit actually declined 5.5% Y/Y due to inventory issues, which masked a 20% jump in international sales. The company warns on FY12 guidance however, now saying it expects revenue in the range of $174M - $176M. Analysts are looking for sales of $176M.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector